(Cont. News of TECHNODRUG): which are historically sold through government tender processes. Over the last two years, sales through government tenders were temporarily halted, which severely impacted our cash flow and led to a delay in servicing our bank loan interest. Of the total interest amount of BDT 21.78 Crore, we have repaid BDT 8.80 Crore, leaving an overdue balance of BDT 12.98 Crore. Furthermore, we were unaware that the bank had initiated the auction process at that stage..." (end)

(Cont. news of TECHNODRUG): Production activities across our factories remain operational. We anticipate that once the tender process resumes, the company's revenue stream and banking operations will swiftly normalize. We assure our valued shareholders, investors, and the DSE authorities that the management is taking all necessary and effective steps to resolve this temporary loan-related challenge at the earliest." (end)

Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the Quarter ended on 30 June 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Techno%20Drugs826.pdf

Emerging Credit Rating Limited (ECRL) has assigned Surveillance rating of the Company as "BBB" in the long term and "ST-3" in the short term along with a Stable outlook based on audited financial statements up to June 30, 2025, quarterly unaudited financial statement up to March 31, 2026, and other relevant quantitative as well as qualitative information up to the date of rating.

Trading of the shares of the company will resume on 11.06.2026.

Trading of the shares of the company will remain suspended on record date i.e., 10.06.2026 for EGM.

Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 08.06.2026 to 9.06.2026 and trading of the shares will remain suspended on record date i.e., 10.06.2026 for EGM.

Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended 31 March, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Techno%20Drugs%20Limited26.pdf

(cont. news of TECHNODRUG): Date of EGM: June 24, 2026 at 11.00 a.m. Record Date for EGM: June 10, 2026. Venue: Using Hybrid System in combination of Digital Platform through the link https://technodrug.hybridegmbd.net and Physical Presence at Institution of Diploma Engineers, 160/A, Kakrail VIP Road, Dhaka 1000. The Board of Directors has also decided to appoint MTB Capital Limited as the Issue Manager and Arranger for the proposed transaction. (end)

(Cont. news of TECHNODRUG): Reasons for significant deviation: The company's EPS has decreased due to lower sales revenue and increased financial expenses compare to the previous period. Net Cash Flow from operation (NOCFPS) increase due to decrease of paid to supplier and others. (end)